ClinicalTrials.Veeva

Menu

How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.

S

Skin Analytics

Status

Active, not recruiting

Conditions

Squamous Cell Cancer
Basal Cell Cancer
Skin Cancer
Melanoma of Skin

Treatments

Device: Deep Ensemble for the Recognition of Malignancy (DERM)

Study type

Observational

Funder types

Industry

Identifiers

NCT06654999
DERM-011

Details and patient eligibility

About

DERM is a Medical Device that uses artificial intelligence to help doctors check if a skin lesion might be cancerous. It works by analysing close-up pictures of skin lesions taken with a smartphone.

This study aims to demonstrate how consistent (precise) the output of DERM is: i.e. does it provide the same result when it analyses multiple photos of the same lesion (repeatability), and when the same lesion is photographed by different people, or with different cameras (reproducibility).

Adults with at least one skin lesion that doctors are checking for cancer, as part of their standard care, will be able to take part. Suitable lesions will be photographed three times, each by three different people using three sets of image capture hardware (specifically, an iPhone 11 with a DL200/HR dermoscopic lens). Each image will be checked for good image quality as it is captured. Images will then be transferred to DERM, where they'll be analysed.

The DERM output won't be shared with the patients or doctors involved in the study. The patients will continue to have their skin lesion biopsy/excised, in accordance with standard of care. Their diagnosis will be collected and compared to the output from DERM.

Enrollment

115 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or Female,
  • aged 18 years or above,
  • Willing and able to give informed consent for participation in the study,
  • Has at least one skin lesion that, following assessment by a primary care provider and a dermatology specialist, will be biopsied due to a high suspicion of skin cancer, and is suitable for assessment by DERM.
  • In the Investigator's opinion, able and willing to comply with all study requirements.

Exclusion criteria

  • Patients with more than one skin lesion due for biopsy
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

To be suitable for inclusion, a skin lesion must NOT have ANY of the following limitations:

  • Be located on an anatomical site of different skin structure: palms of hands or soles of feet (acral lesion), mucosal surfaces (lips and eyes) or under nail (ungal lesion),
  • Have a diameter greater than the diameter of the dermoscopic lens,
  • Be located on an anatomical site unsuitable for photographing, including on surface of genitals and hair-bearing areas,
  • Have been previously biopsied, excised, treated or is otherwise traumatised
  • Be located in an area of visible scarring or tattooing.

Trial design

115 participants in 1 patient group

All patients
Description:
All patients will have their skin lesion imaged in the same way
Treatment:
Device: Deep Ensemble for the Recognition of Malignancy (DERM)

Trial contacts and locations

3

Loading...

Central trial contact

Clinical Research Director

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems